Houston Methodist Joins $49 Million National Consortium to Develop AI-Driven Herpesvirus Vaccine

Houston Methodist Joins National Consortium for Herpesvirus Vaccine Development

Houston Methodist researchers have joined a national consortium awarded up to $49 million by the U.S. Government's Advanced Research Projects Agency for Health (ARPA-H) to develop vaccines against two common and destructive strains of herpesviruses 1

1

2

2

. This initiative, part of ARPA-H's Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx) program, aims to create both prophylactic and therapeutic vaccines targeting β- and γ- herpesviruses.

The SHIELD Project and Its Objectives

The America's SHIELD (Strategic Herpesvirus Immune Evasion and Latency Defense) project will focus on developing an integrated computational toolkit for antigen engineering 1

1

. This approach has the potential to revolutionize vaccine development against various pathogens, including human cytomegalovirus and Epstein-Barr virus, which affect a large proportion of the U.S. population at an annual cost of at least $4 billion 2

2

.

Impact of Target Herpesviruses

Epstein-Barr virus is known to cause mononucleosis in adolescents and young adults, and is associated with various cancers and autoimmune diseases 1

1

. Human cytomegalovirus, on the other hand, is the leading cause of congenital birth defects, potentially resulting in permanent hearing loss or neurodevelopmental impairments, particularly affecting socioeconomically disadvantaged children 2

2

.

Houston Methodist's Role and Expertise

Jimmy D. Gollihar, Ph.D., head of the Antibody Discovery & Accelerated Protein Therapeutics (ADAPT) laboratory at Houston Methodist Research Institute, is a co-principal investigator in the consortium 1

1

. As an AI and machine learning expert, Gollihar will generate new gene sequences encoding viral antigens for mRNA vaccines 2

2

. His team's experience during the COVID-19 pandemic in genomic surveillance, antigen production, and antibody engineering will be valuable to the project.

Innovative Approach to Vaccine Development

The consortium's strategy involves targeting antigens essential to various stages of viral infection, including cell-to-cell spread, immune evasion, and reactivation stages linked to cancer and autoimmune diseases 1

1

. This comprehensive approach aims to address multiple aspects of viral pathogenesis.

Collaborative Efforts and Technological Integration

Other key Houston Methodist researchers involved in the project include:

1. John P. Cooke, M.D., Ph.D., medical director of the Center for RNA Therapeutics, who will lead the generation of mRNA herpesvirus vaccines 2

   2

   .
2. Francesca Taraballi, Ph.D., director of the Center for Musculoskeletal Regeneration, who will provide a nanoscale drug delivery platform using lipid nanoparticles (LNPs) 1

   1

   .

Potential Impact and Future Applications

By integrating advanced computational models with immunological data, this multidisciplinary approach aims to accelerate herpesvirus vaccine development and enable rapid design of immunizing agents against various viruses 2

2

. This could potentially transform vaccine development processes and improve preparedness for future pandemics.

The project's success could have far-reaching implications, not only in combating herpesviruses but also in developing a framework for rapid response to emerging viral threats, marking a significant advancement in vaccine technology and public health preparedness 1

1

2

2

.